COVID-19: Omicron-specific Sinopharm, Sinovac vaccine candidates cleared for clinical trial in Hong Kong

The two candidates from units of Sinopharm subsidiary China National Biotec Group (CNBG) and one from Sinovac contain inactivated or “killed” coronavirus.
( read original story …)

---